Bahrain vs Central African Republic: Access to anti-retroviral drugs, female
Bahrain
73.0%
in 2024
Central African Republic
73.0%
in 2024
Bahrain rank
71st
Central African Republic rank
71st
Access to anti-retroviral drugs, female over time
- Bahrain
- Central African Republic
How they compare
Bahrain currently reports 73.0% against 73.0% in Central African Republic, a difference of 0.0%.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Bahrain ahead.
Bahrain ranks 71st and Central African Republic ranks 71st of 141 countries.
Bahrain has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bahrain | Central African Republic | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 25.1% | 2.4% | 22.7% | Bahrain |
| 2010s | 56.6% | 26.1% | 30.5% | Bahrain |
| 2020s | 73.8% | 65.6% | 8.2% | Bahrain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Bahrain or Central African Republic?
- Bahrain, at 73.0% against 73.0% in Central African Republic as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Bahrain and Central African Republic?
- 0.0%, with Bahrain ahead.
- How many years of comparable data are there for Bahrain and Central African Republic?
- 25 years are reported by both, from 2000 to 2024.
- How do Bahrain and Central African Republic rank globally for access to anti-retroviral drugs, female?
- Bahrain ranks 71st and Central African Republic ranks 71st of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.